The CDSCO said advertisements — including surrogate promotions — across print, electronic, digital or social media platforms ...

The Drugs Controller General of India (DCGI) has issued strict warning against any surrogate advertisements, including awareness campaigns, for presc ...

India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has warned pharmaceutical companies against direct or indirect promotion of prescription weight-loss medicines, ...

By Rishika Sadam March 11 (Reuters) - India's drug regulator has warned pharmaceutical companies against direct or indirect advertising of weight-loss medicines, including obesity awareness campaigns ...

India's drug regulator, Central Drugs Standard Control Organisation (CDSCO), has prohibited all direct and indirect promotional activities for glucagon-like peptide-1 (GLP-1) receptor agonist drugs, ...

The Drugs Controller General of India (DCGI) has issued strict warning against promotional activities, including “awareness campaigns," that functions as a surrogate advertisement for ...

The Drugs Controller General of India (DCGI) has issued strict warning against any surrogate advertisements, including awareness campaigns, for presc ...

India’s CDSCO warns pharma companies against promoting prescription weight-loss drugs like Semaglutide and Liraglutide to the public, urging ethical marketing and holistic obesity care.

Advisory cautions companies against surrogate advertising of prescription GLP-1 therapies ...

India's CDSCO has warned pharma firms against promoting prescription weight-loss drugs (GLP-1s) via surrogate or digital ads, ...

Any advertisement, direct or indirect, that promotes prescription medicines to the general public, inflates efficacy claims or implies guaranteed weight loss outcomes will be deemed misleading and can ...

India's drug regulator has prohibited pharmaceutical companies from advertising weight-loss medicines directly or indirectly, including through obesity awareness campaigns.